Published in final edited form as:

Biochem Biophys Res Commun. 2014 July 18; 450(1): 341–346. doi:10.1016/j.bbrc.2014.05.122.

Negative Feedback Regulation of NF- κ B-Inducing Kinase is Proteasome-Dependent But Does Not Require Cellular Inhibitors of Apoptosis

Carolyn M. Gray^a, Kelly A. McCorkell^a, Srinivas K. Chunduru^b, Mark A. McKinlay^c, and Michael J. May^{a,d,*}

^aDepartment of Animal Biology, University of Pennsylvania School of Veterinary Medicine, 3800 Spruce Street, Philadelphia, PA 19104

^bPKPD Biosciences, 717 Constitution Drive, Suite 104, Exton, PA 19341

^cTask Force for Global Health, 325 Swanton Way, Decatur, GA, 30030

^dMari Lowe Center for Comparative Oncology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA 19104

Abstract

Non-canonical NF- κ B signaling is controlled by the precise regulation of NF- κ B Inducing Kinase (NIK) stability. NIK is constitutively ubiquitinated by cellular inhibitor of apoptosis (cIAP) proteins 1 and 2, leading to its complete proteasomal degradation in resting cells. Following stimulation, cIAP-mediated ubiquitination of NIK ceases and NIK is stabilized, allowing for Inhibitor of κ B kinase (IKK) α activation and non-canonical NF- κ B signaling. Non-canonical NF- κ B signaling is terminated by feedback phosphorylation of NIK by IKK α that promotes NIK degradation; however, the mechanism of active NIK protein turnover remains unknown. To address this question, we established a strategy to precisely distinguish between basal degradation of newly synthesized endogenous NIK and induced active NIK in stimulated cells. Using this approach, we found that IKK α -mediated degradation of signal-induced activated NIK occurs through the proteasome. To determine whether cIAP1 or cIAP2 play a role in active NIK turnover, we utilized a Smac mimetic (GT13072), which promotes degradation of these E3 ubiquitin ligases. As expected, GT13072 stabilized NIK in resting cells. However, loss of the cIAPs did not inhibit proteasome-dependent turnover of signal-induced NIK showing that unlike the basal regulatory mechanism, active NIK turnover is independent of cIAP1 and cIAP2. Our results therefore establish that the negative feedback control of IKK α -mediated NIK turnover occurs via a novel proteasome-dependent and cIAP-independent mechanism.

© 2014 Elsevier Inc. All rights reserved.

*Corresponding author: Dr. Michael J. May, Department of Animal Biology, School of Veterinary Medicine, University of Pennsylvania, Room 200E OVH, 3800 Spruce Street Philadelphia, PA 19104, Tel.: 215-573-0940. maym@vet.upenn.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

NIK; cIAP; NF- κ B; Smac mimetic; proteasome; bortezomib

1. Introduction

NF- κ B activation occurs by two separate mechanisms: the classical and non-canonical NF- κ B pathways. Classical NF- κ B signaling is vital for host immunity, cellular survival and proliferation, and the inflammatory response [1,2]. Non-canonical NF- κ B activity is required for lymph node organogenesis and B cell development [3,4,5]; however, increasing evidence implicates aberrant non-canonical signaling in chronic inflammatory diseases and cancers [5,6,7]. Consequently, defining the mechanisms that regulate both the activation and down-regulation of non-canonical NF- κ B signaling is crucial for the development of novel therapeutic strategies to selectively block this pathway.

Non-canonical NF- κ B signaling is controlled by NF- κ B Inducing Kinase (NIK) protein stability [3,5]. NIK is continuously translated in resting cells [8] but is normally undetectable due to the activity of a regulatory complex containing TRAF2, TRAF3, cIAP1 and cIAP2. NIK associates with this complex by binding TRAF3, which associates with cIAP1/2-bound TRAF2 [9,10,11]. cIAP1 and cIAP2 are E3 ubiquitin ligases which target newly synthesized NIK for proteasomal degradation in unstimulated cells [11,12]. The cIAPs act redundantly, as silencing both cIAP1 (*Birc2*) and cIAP2 (*Birc3*) is required to stabilize NIK in resting cells [11]. Following ligation of receptors such as the lymphotoxin- β receptor (LT R) that activate the non-canonical pathway, the ubiquitin ligase activity of cIAP1/2 is redirected to TRAF3, which releases NIK from the negative regulatory complex and permits its stabilization [13].

Stable NIK is constitutively active [14] and phosphorylates and activates Inhibitor of Kappa-B Kinase (IKK) α . Active IKK α phosphorylates the NF- κ B precursor p100 leading to its proteasomal processing to p52. p52 bound to RelB translocates to the nucleus to regulate a discrete panel of genes involved in lymph node organogenesis and B cell maturation [15,16].

The duration of non-canonical NF- κ B signaling is controlled by a crucial negative regulatory mechanism in which activated IKK α feeds back to phosphorylate NIK at C-terminal serine residues [17]. These modifications promote NIK turnover, however, the precise mechanism of IKK α -induced NIK degradation remains unknown. Overexpression and inhibitor studies suggest that the TRAF2/3:cIAP1/2 complex that controls the basal turnover of newly synthesized NIK does not require prior NIK phosphorylation [17]. Importantly, these experiments did not directly address a potentially distinct role for the cIAPs in controlling the turnover of activated endogenous NIK. As the cIAPs are, to date, the only known regulators of basal NIK stability, we sought to determine whether cIAP1 and cIAP2 are required for the negative turnover of active NIK.

To precisely differentiate between the endogenous degradation of newly synthesized NIK in resting cells and active NIK in LT β R-stimulated cells, we employed proteasome and protein synthesis inhibitors. Using this approach we have definitively determined that signal-

induced active NIK is rapidly degraded by the proteasome. Furthermore, we used a novel Smac mimetic that promotes degradation of cIAP1 and cIAP2, and found that unlike the basal regulatory mechanism, active endogenous NIK turnover does not require the cIAPs. Our findings establish that the negative feedback control of IKK α -induced NIK turnover occurs via a novel proteasome-dependent but cIAP-independent mechanism.

2. Materials and Methods

2.1. Cell Lines and Culture

3T3-NIH Mouse Embryonic Fibroblasts and HeLa cells were from ATCC. IKK α ^{KO} MEFs were from Inder Verma (The Salk Institute, San Diego, CA). All cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% fetal bovine serum (Atlanta Biologics), 2mM L-glutamine, penicillin (50 units/mL) and streptomycin (50 units/mL). Cells were stimulated when they reached 80% confluence.

2.2. Antibodies and reagents

Recombinant human LIGHT, anti-cIAP1, and pan-cIAP antibodies were from R&D Systems. Anti-NIK and -mouse p100/p52 were from Cell Signaling Technology. Anti-human p100/p52 was from Millipore. Anti-I κ B α was from Santa Cruz Biotechnology and anti-NEMO was from MBL International. Anti-IKK α was from Imgenex and monoclonal anti-cIAP1 was from Enzo Life Sciences. Horseradish Peroxidase-conjugated secondary antibodies were from Jackson Immuno Research. Agonistic antibody against the LT β R (5G11) was from Abcam. Protein λ -phosphatase was from New England Biosciences. Anti- α -Tubulin and MG132 were from Sigma-Aldrich. Bortezomib was a generous gift from Katherine A. High, M.D. (The Children's Hospital of Philadelphia). Bortezomib was used at a final concentration of 500nM. Cells were treated with 0.05% DMSO as a control. Cycloheximide was from EMD Millipore and used a final concentration of 2.5 μ g/mL. As a control, cells were treated with 0.1% ethanol. The active Smac mimetic GT13072 and the inactive Smac mimetic GT13199 were generously provided by TetraLogic Pharmaceuticals (Malvern, PA). Smac mimetics were used at a final concentration of 1 μ M. Cells were treated with 0.1% DMSO as a control.

2.3. Immunoblotting

Cells were harvested on ice in a lysis buffer consisting of 150mM NaCl, 50mM TrisCl pH 7.5, 1% Triton X-100, and complete protease inhibitors (Roche). Twenty μ g of total protein was separated by SDS-PAGE and transferred onto PVDF membrane (Millipore). The immunoblots presented are one of three representative experiments developed using enhanced chemiluminescence.

3. Results

3.1. Active NIK is turned over rapidly by the proteasome

To examine NIK stabilization in WT MEFs, we incubated cells with LIGHT (TNFSF14) for up to eight hours. As expected, NIK was in low abundance in resting WT cells but was detected following treatment with LIGHT, with maximal levels occurring after four hours of

incubation (Fig. 1A). Consistent with a negative regulatory role for IKK α in controlling NIK turnover [17], abundant NIK was detected in resting IKK α ^{KO} MEFs and could be further elevated with LIGHT stimulation (Fig. 1A). Notably, the electrophoretic mobility of NIK in both resting and LIGHT-stimulated IKK α ^{KO} MEFs was greater than active NIK in WT MEFs, which was consistently detected as a doublet (Fig. 1A, compare lanes 5 and 11). We incubated samples with γ -phosphatase to determine that active NIK in WT MEFs was phosphorylated (Fig. 1B, lanes 1 and 2). In contrast, the lower molecular weight NIK in IKK α ^{KO} cells was unaffected by phosphatase treatment indicating that NIK is unphosphorylated in the absence of IKK α (Fig. 1B).

To specifically analyze the turnover of active NIK, MEFs were stimulated with LIGHT to increase NIK abundance then incubated with cycloheximide (CHX) to block protein synthesis. This approach allowed us to exclude newly synthesized NIK and specifically examine the turnover of LIGHT-activated NIK. As shown in Figure 1C (left panel), active NIK in WT MEFs was rapidly turned over during CHX treatment and was undetectable within 45 minutes of CHX chase. In contrast, LIGHT-induced NIK in IKK α -deficient MEFs remained elevated above basal amounts even after sixty minutes of CHX (Fig. 1C; right panel) confirming that IKK α is required for efficient turnover of active NIK. Together these findings support the IKK α -dependent negative feedback model for non-canonical NF- κ B signaling termination [17]. Importantly, these data also establish that active NIK turnover is rapid, with complete loss of detectable NIK occurring within 30-45 minutes of signal-induced release from the basal regulatory complex.

We next asked if the proteasome plays a role in the IKK α -dependent turnover of endogenous signal-induced NIK. Consistent with previous reports [8,9,10,11,13,18], pharmacological blockade of the proteasome using MG132 led to NIK accumulation in resting cells (Fig. 2A, lane 2), indicating that basal NIK is constitutively degraded through the proteasome. However, analysis of proteasome inhibition on the fate of signal-induced NIK is complicated by concomitant effects on basal NIK levels (Fig. 2A). We therefore used a combination of proteasome and protein synthesis inhibition to isolate signal-induced NIK. Importantly, NIK was undetectable in resting cells co-treated with MG132 and CHX, confirming that in the absence of proteasome function, protein synthesis inhibition prevents NIK accumulation (Fig. 2A). We therefore employed this strategy to determine the effects of proteasome inhibition on active NIK turnover. As shown in Figure 2B, LIGHT treatment induced NIK accumulation in WT MEFs and further incubation in CHX led to the loss of detectable NIK (lane 3). Moreover, inhibition of the proteasome with concomitant CHX treatment inhibited LIGHT-induced NIK turnover (lane 4), indicating that NIK degradation is proteasome-dependent. Notably, inhibition of the proteasome in the absence of CHX led to increased accumulation of NIK in LIGHT-stimulated cells (Fig. 2B, lane 6), further signifying that CHX treatment isolated active NIK from the constitutively translated basal protein.

As MG132 may have off-target effects *in vitro* [19], we also utilized the more selective inhibitor bortezomib (Velcade, PS-341) to confirm the role of the proteasome in active NIK turnover. Similar to MG132, bortezomib inhibits the chymotrypsin-like enzymatic site of the 20S core particle [20]. As expected, both inhibitors blocked TNF-induced proteasome-

dependent degradation of I κ B α in the classical NF- κ B signaling pathway [1] (Fig. 2C). Importantly, the turnover of LIGHT-induced NIK was blocked by pretreatment with either MG132 or bortezomib (Fig. 2D). These data establish, with two different pharmacological inhibitors, that the IKK α -dependent turnover of LIGHT-induced endogenous NIK is proteasome-dependent.

3.2. Turnover of active NIK is independent of cIAP1 and cIAP2

The sensitivity of NIK turnover to proteasome inhibition suggests that active NIK is ubiquitinated, thereby targeting it for degradation. As cIAP1 and cIAP2 (cIAP1/2) are currently the only E3 ubiquitin ligases implicated in NIK regulation [10,11], we hypothesized that in addition to controlling the degradation of newly synthesized NIK, cIAP1/2 also ubiquitinated active, phosphorylated NIK. To assess the requirement of cIAP1/2 in NIK turnover, we used a Smac mimetic compound (GT13072) to degrade endogenous cIAP1/2 [21]. GT13072 treatment led to the rapid loss of cIAP1 and induction of NIK in resting MEFs, whereas an inactive compound (GT13199) did not (Fig. 3A). GT13072 treatment induced NIK stabilization and p100 processing more rapidly than LIGHT (Fig. 3B). Furthermore, GT13072 treatment induced a second NIK band in WT MEFs but not IKK α ^{KO} MEFs (Fig. 3C), and λ -phosphatase treatment showed that this band represents phosphorylated NIK (Fig. 3D). Thus release of NIK from the control of the TRAF2/3:cIAP1/2 complex promotes its stabilization and phosphorylation similar to that induced by the natural ligand LIGHT or a LT β R cross-linking antibody (Fig. 3C, lane 11). We therefore used GT13072 to determine if cIAPs are further required to promote turnover of active NIK. To specifically isolate GT13072-induced NIK from basally translated NIK, we employed the CHX chase approach established in Figure 1C. Similar to LIGHT-induced NIK, NIK stabilized by GT13072 was turned over within sixty minutes of CHX treatment, despite the absence of cIAP1 (Fig. 3E). Thus, cIAP1 is dispensable for the turnover of active NIK in MEFs.

Although we were unable to detect resting cIAP2 protein in MEFs, NIK was stabilized by GT13072 treatment alone (Fig. 3A). As cIAP1 and cIAP2 have been shown to be functionally redundant in basal NIK regulation [11], this suggested that GT13072 also degraded any endogenous cIAP2. However, to definitively determine that cIAP1 and cIAP2 do not play distinct roles in active NIK turnover, we assessed NIK regulation in HeLa cells, which express both cIAP1 and cIAP2 (Fig. 4A). GT13072 treatment led to the rapid loss of cIAP1 and cIAP2 in HeLa cells followed by NIK stabilization (Fig. 4A). As in MEFs, treatment with GT13072 induced p100 processing similar to the natural ligand LIGHT (Fig. 4B). Importantly, using CHX to distinguish active NIK from basally translated protein revealed that negative regulation of active NIK was intact in HeLa cells after cIAP1/2 degradation (Fig. 4C). These results thereby establish that endogenous cIAP1 and cIAP2 are dispensable for the turnover of active NIK.

3.3. NIK turnover in the absence of cIAP1/2 occurs through the proteasome

Thus far we have established that active NIK turnover induced by LIGHT requires the proteasome. Moreover, turnover of GT13072-stabilized NIK occurs in the absence of cIAP1/2 in both MEFs and HeLa cells. We therefore questioned whether GT13072-induced

NIK turnover required the proteasome. To specifically follow the destabilization of active NIK induced by GT13072, we employed the co-treatment strategy described in Figure 2. Similar to the effects in MEFs (Fig. 2A), treatment of HeLa cells with MG132 stabilized basal NIK, a process that was dependent on new protein synthesis (not shown). We next induced NIK using GT13072 and assessed the effect of MG132 on NIK turnover. Figure 5 shows that in both HeLa cells and MEFs, NIK turnover is blocked by co-incubation of MG132 with CHX (Fig. 4D, lanes 3 and 4). Thus we conclude that unlike basal NIK turnover, which absolutely requires cIAP1/2 [10,11], proteasome-dependent turnover of active endogenous NIK does not require the cIAPs. Together, our data support a model in which the negative feedback control of IKK α -induced NIK turnover is proteasome-dependent but cIAP-independent (Fig. 4E).

4. Discussion

Pathologies associated with aberrant non-canonical NF- κ B signaling underscore the importance of fully elucidating the mechanisms of NIK regulation. Genetic alterations in the basal regulatory complex have been associated with multiple myeloma and melanoma in humans. [7,22,23,24]. More recently, blocking either the ubiquitin ligase activity of cIAP2 or the negative turnover of active NIK have been shown to result in B cell hyperplasia and kidney nephropathy in mice [25,26]. As controlling non-canonical NF- κ B signaling depends on the stabilization of NIK, defining NIK regulatory mechanisms is crucial for the development of novel therapeutic strategies aimed at selectively manipulating this pathway.

IKK α -mediated negative feedback control of non-canonical NF- κ B signaling requires the phosphorylation of NIK [17]. Here we show that this post-translational modification directs the active kinase to the proteasome for degradation. The most common mechanism of signal-induced proteasomal targeting is ubiquitylation [27,28], and previous overexpression studies have shown that NIK can be ubiquitylated by exogenous cIAP1 or cIAP2 [10,11,17]. Yet these experiments did not distinguish between ubiquitylation of basally translated NIK and NIK stabilized by activating ligands.

We have previously shown that TRAF3 is dispensable for active NIK turnover [29]. However, since cIAP1/2 are the only E3 ubiquitin ligases known to target NIK directly, we hypothesized that cIAP1/2 might play a TRAF3-independent role in the turnover of active NIK. Our results using the Smac mimetic GT13072 indicate that loss of cIAP1/2 has no effect on the turnover of active NIK. Thus we conclude that ubiquitylation of NIK by cIAP1/2 is limited to only the newly synthesized protein controlled by the basal TRAF3:TRAF2 regulatory complex. Our data therefore suggest that phosphorylated NIK is ubiquitylated by a currently unidentified E3 ubiquitin ligase. One potential candidate is SCF $^{\beta$ TrCP, which ubiquitylates I κ B α in the classical NF- κ B pathway [1]. Whether β TrCP or another E3 ubiquitin ligase controls active NIK turnover will be an important area of future research to selectively manipulate the duration of non-canonical NF- κ B activity.

Our finding that the turnover of NIK absolutely requires the proteasome strongly suggests that active NIK is ubiquitylated. Despite intense efforts, we have been unable to detect ubiquitylation of endogenous NIK under any conditions. As we have ruled out the cIAPs as

E3 ubiquitin ligases targeting NIK, an alternative possibility is that active NIK is phosphorylated by IKK α and degraded by the 20S proteasome via a ubiquitin-independent mechanism. While such a mechanism is rare, several proteins including p53 and ornithine decarboxylase (ODC) can be degraded “by default” [28,30,31]. Our results cannot conclusively eliminate this possibility and ubiquitin-independent degradation of active NIK is an intriguing mechanism to consider.

Collectively our findings separate the molecular requirements for active NIK turnover from those involved in the basal regulation of newly translated protein, revealing a previously unappreciated layer of NIK regulation. Increasing reports of dysregulated non-canonical NF- κ B signaling in disease [4,6,7] and the critical role of NIK stabilization in non-canonical NF- κ B [3] underscore the importance of fully elucidating the mechanism of active NIK turnover to develop novel therapeutic strategies to terminate the non-canonical NF- κ B signaling pathway.

Acknowledgments

We thank TetraLogic Pharmaceuticals for Smac mimetic compounds, Katherine High for bortezomib, and Inder Verma for IKK α ^{KO} MEFs. We thank Leslie King for critically reading the manuscript. Supported by NIH T32 GM-07229 and AHA Great Rivers Pre-doctoral Fellowship 11PRE7540013 to CMG; NIH R01 HL096642 to MJM.

Abbreviations

NIK	NF- κ B inducing kinase
cIAP	Cellular inhibitors of apoptosis
IKK	Inhibitor of κ B kinase

References

- Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. *Cell*. 2008; 132:344–362. [PubMed: 18267068]
- Hayden MS, Ghosh S. NF-kappaB in immunobiology. *Cell Res*. 2011; 21:223–244. [PubMed: 21243012]
- Sun SC. Controlling the fate of NIK: a central stage in noncanonical NF-kappaB signaling. *Sci Signal*. 2010; 3:pe18. [PubMed: 20501935]
- Sun SC. Non-canonical NF-kappaB signaling pathway. *Cell Res*. 2011; 21:71–85. [PubMed: 21173796]
- Sun SC. The noncanonical NF-kappaB pathway. *Immunol Rev*. 2012; 246:125–140. [PubMed: 22435551]
- Razani B, Reichardt AD, Cheng G. Non-canonical NF-kappaB signaling activation and regulation: principles and perspectives. *Immunol Rev*. 2011; 244:44–54. [PubMed: 22017430]
- Thu YM, Richmond A. NF-kappaB inducing kinase: a key regulator in the immune system and in cancer. *Cytokine Growth Factor Rev*. 2010; 21:213–226. [PubMed: 20685151]
- Qing G, Qu Z, Xiao G. Stabilization of basally translated NF-kappaB-inducing kinase (NIK) protein functions as a molecular switch of processing of NF-kappaB2 p100. *J Biol Chem*. 2005; 280:40578–40582. [PubMed: 16223731]
- Liao G, Zhang M, Harhaj EW, Sun SC. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. *J Biol Chem*. 2004; 279:26243–26250. [PubMed: 15084608]

10. Vallabhapurapu S, Matsuzawa A, Zhang W, Tseng PH, Keats JJ, Wang H, Vignali DA, Bergsagel PL, Karin M. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. *Nat Immunol.* 2008; 9:1364–1370. [PubMed: 18997792]
11. Zarnegar BJ, Wang Y, Mahoney DJ, Dempsey PW, Cheung HH, He J, Shiba T, Yang X, Yeh WC, Mak TW, Korneluk RG, Cheng G. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. *Nat Immunol.* 2008; 9:1371–1378. [PubMed: 18997794]
12. Varfolomeev E, Goncharov T, Maecker H, Zobel K, Komuves LG, Deshayes K, Vucic D. Cellular inhibitors of apoptosis are global regulators of NF-kappaB and MAPK activation by members of the TNF family of receptors. *Sci Signal.* 2012; 5:ra22. [PubMed: 22434933]
13. Sanjo H, Zajonc DM, Braden R, Norris PS, Ware CF. Allosteric regulation of the ubiquitin:NIK and ubiquitin:TRAF3 E3 ligases by the lymphotoxin-beta receptor. *J Biol Chem.* 2010; 285:17148–17155. [PubMed: 20348096]
14. Liu J, Sudom A, Min X, Cao Z, Gao X, Ayres M, Lee F, Cao P, Johnstone S, Plotnikova O, Walker N, Chen G, Wang Z. Structure of the nuclear factor kappaB-inducing kinase (NIK) kinase domain reveals a constitutively active conformation. *J Biol Chem.* 2012; 287:27326–27334. [PubMed: 22718757]
15. Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC, Karin M. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. *Science.* 2001; 293:1495–1499. [PubMed: 11520989]
16. Dejardin E, Droin NM, Delhase M, Haas E, Cao Y, Makris C, Li ZW, Karin M, Ware CF, Green DR. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. *Immunity.* 2002; 17:525–535. [PubMed: 12387745]
17. Razani B, Zarnegar B, Ytterberg AJ, Shiba T, Dempsey PW, Ware CF, Loo JA, Cheng G. Negative feedback in noncanonical NF-kappaB signaling modulates NIK stability through IKKalpha-mediated phosphorylation. *Sci Signal.* 2010; 3:ra41. [PubMed: 20501937]
18. Matsushima A, Kaisho T, Rennert PD, Nakano H, Kurosawa K, Uchida D, Takeda K, Akira S, Matsumoto M. Essential role of nuclear factor (NF)-kappaB-inducing kinase and inhibitor of kappaB (IkappaB) kinase alpha in NF-kappaB activation through lymphotoxin beta receptor, but not through tumor necrosis factor receptor I. *J Exp Med.* 2001; 193:631–636. [PubMed: 11238593]
19. Kisselev AF, van der Linden WA, Overkleeft HS. Proteasome inhibitors: an expanding army attacking a unique target. *Chem Biol.* 2012; 19:99–115. [PubMed: 22284358]
20. Goldberg AL. Development of proteasome inhibitors as research tools and cancer drugs. *J Cell Biol.* 2012; 199:583–588. [PubMed: 23148232]
21. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, Zobel K, Dynek JN, Elliott LO, Wallweber HJ, Flygare JA, Fairbrother WJ, Deshayes K, Dixit VM, Vucic D. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. *Cell.* 2007; 131:669–681. [PubMed: 18022362]
22. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy JD Jr. Kuehl WM, Staudt LM. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. *Cancer Cell.* 2007; 12:115–130. [PubMed: 17692804]
23. Dhawan P, Su Y, Thu YM, Yu Y, Baugher P, Ellis DL, Sobolik-Delmaire T, Kelley M, Cheung TC, Ware CF, Richmond A. The lymphotoxin-beta receptor is an upstream activator of NF-kappaB-mediated transcription in melanoma cells. *J Biol Chem.* 2008; 283:15399–15408. [PubMed: 18347013]
24. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M, Braggio E, Henry T, Zhu YX, Fogle H, Price-Troska T, Ahmann G, Mancini C, Brents LA, Kumar S, Greipp P, Dispenzieri A, Bryant B, Mulligan G, Bruhn L, Barrett M, Valdez R, Trent J, Stewart AK, Carpten J, Bergsagel PL. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. *Cancer Cell.* 2007; 12:131–144. [PubMed: 17692805]

25. Conze DB, Zhao Y, Ashwell JD. Non-canonical NF-kappaB activation and abnormal B cell accumulation in mice expressing ubiquitin protein ligase-inactive c-IAP2. *PLoS Biol.* 2010; 8:e1000518. [PubMed: 21048983]
26. Jin J, Xiao Y, Chang JH, Yu J, Hu H, Starr R, Brittain GC, Chang M, Cheng X, Sun SC. The kinase TBK1 controls IgA class switching by negatively regulating noncanonical NF-kappaB signaling. *Nat Immunol.* 2012; 13:1101–1109. [PubMed: 23023393]
27. Pickart CM. Targeting of substrates to the 26S proteasome. *FASEB J.* 1997; 11:1055–1066. [PubMed: 9367341]
28. Finley D. Recognition and processing of ubiquitin-protein conjugates by the proteasome. *Annu Rev Biochem.* 2009; 78:477–513. [PubMed: 19489727]
29. Gray CM, Remouchamps C, McCorkell KA, Solt LA, Dejardin E, Orange JS, May MJ. Noncanonical NF-kappaB Signaling Is Limited by Classical NF-kappaB Activity. *Sci Signal.* 2014; 7:ra13. [PubMed: 24497610]
30. Tsvetkov P, Reuven N, Shaul Y. Ubiquitin-independent p53 proteasomal degradation. *Cell Death Differ.* 2010; 17:103–108. [PubMed: 19557012]
31. Asher G, Reuven N, Shaul Y. 20S proteasomes and protein degradation “by default”. *Bioessays.* 2006; 28:844–849. [PubMed: 16927316]

Highlights

- Activation-induced endogenous NIK is degraded via the proteasome.
- The Smac mimetic GT13072 activates non-canonical NF- κ B signaling.
- GT13072 does not block active NIK degradation.
- The requirements for active and basal NIK turnover are distinct.

Fig. 1.

IKKα is required for the turnover of active NIK. (A) WT or IKKα-deficient (IKKα^{KO}) MEFs were treated with LIGHT (100ng/ml) for the times indicated. Whole cell extracts were immunoblotted for the indicated proteins. (B) WT or IKKα^{KO} MEFs were treated with LIGHT for four hours to stabilize NIK. Whole cell extracts were then treated with protein λ-phosphatase and immunoblotted for NIK. * indicates the phosphorylated protein. (C) WT or IKKα^{KO} MEFs were treated as in (B), followed by 2.5 μg/ml cycloheximide (CHX) or vehicle (V) for the times indicated. Lysates were immunoblotted for the indicated proteins.

Fig. 2.

Active NIK is degraded via the proteasome in MEFs. (A) WT MEFs were treated with 10 μ M MG132 (+), or MG132 plus 2.5 μ g/ml cycloheximide (C) or vehicle control (V) for one hour. Whole cell lysates were immunoblotted with antibodies against the indicated proteins. (B) WT MEFs were treated with LIGHT for four hours followed by one hour of cycloheximide (C) or vehicle (V) in the absence or presence of MG132 (+) to inhibit the proteasome. Lysates were immunoblotted as in (A). (C) WT MEFs were either left untreated or incubated with 500nM MG132 or 500nM bortezomib for 8 hours. Cells were then stimulated with TNF for 15 minutes. Lysates were immunoblotted with antibodies against the indicated proteins. (D) WT MEFs were treated with 500nM MG132 or 500nM bortezomib, with (+) or without (–) LIGHT for 6.5 hours and subsequently incubated with cycloheximide (C) or vehicle (V) for 90 minutes. Lysates were immunoblotted as in (A).

Fig. 3.

The Smac mimetic GT13072 does not block NIK turnover in MEFs. (A) WT MEFs were treated for four hours with either 1 μ M GT13072 or the inactive compound GT13199. Cells were lysed and immunoblotted for the indicated proteins. (B) WT MEFs were treated with LIGHT or GT13072 for the times indicated. Lysates were immunoblotted for the indicated proteins. (C) WT or IKK α ^{KO} MEFs were treated with GT13072, GT13199, or anti-LT β R Ab for up to 24 hours. Lysates were immunoblotted as in (A). (D) WT or IKK α ^{KO} MEFs were treated with GT13072 for four hours to stabilize NIK. Whole cell extracts were treated with protein λ -phosphatase and immunoblotted for NIK. (E) WT MEFs were stimulated with either LIGHT or GT13072 for four hours, followed by either 2.5 μ g/ml cycloheximide (CHX) for up to one hour or vehicle (V) for one hour. Lysates were immunoblotted as in (A).

Fig. 4.

cIAP1/2 are not required for proteasome-dependent NIK turnover in HeLa cells. (A) HeLa cells were treated for four hours with either 1 μ M GT13072 or GT13199. Cells were lysed and immunoblotted for the indicated proteins. (B) HeLa cells were treated with LIGHT or GT13072 for the times indicated. Lysates were immunoblotted for the indicated proteins. (C) HeLa cells were stimulated with either LIGHT or GT13072 for four hours. Cells were then treated with 2.5 μ g/ml cycloheximide (CHX) for up to one hour (V, vehicle control). Cells were lysed and immunoblotted for the indicated proteins. (D) HeLa cells or WT MEFs were treated as in (C) plus 10 μ M MG132 (+) for one hour (C, cycloheximide; V, vehicle control). Lysates were immunoblotted for the indicated proteins. (E) In unstimulated cells scant NIK abundance is maintained by a complex consisting of TRAF2 (T2), TRAF3 (T3) and cIAP1/2. The cIAPs ubiquitylate newly synthesized NIK (black circles) leading to its rapid proteasomal degradation (*left side*). Following ligation of receptors that activate non-canonical NF- κ B, the basal regulatory complex is disrupted and NIK protein increases to detectable levels. Accumulated NIK then associates with and activates IKK α leading to induction of non-canonical NF- κ B (*right side*). Activated IKK α also feeds back to phosphorylate NIK (P) triggering its degradation by the proteasome. Unlike basal NIK turnover, this feedback degradation of active NIK does not require cIAP1/2.